Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.

: Characteristic of some rare pediatric and adult malignancies, addiction to the oncogene family is also observed in a small fraction of common cancers. Inhibition of their protein products, the Trk kinases, proved a successful treatment strategy for these tumors.: The current paper reviews the clinical development of larotrectinib, a selective inhibitor of the Trk kinase family, for the treatment of fusion-positive cancers. The manuscript includes an overview of the efficacy, safety, pharmacokinetics and pharmacodynamics. The authors sum up by providing the reader with their expert opinion on larotrectinib and its potential future use.: Larotrectinib showed tolerability and high efficacy, regardless of the primary site. In 2018, larotrectinib was granted by the Food and Drug Administration a tissue-agnostic approval for the treatment of solid tumors harboring an fusion. The major challenges will be the implementation of the screening for fusions in the general oncologic population, and the incorporation of larotrectinib into the therapeutic algorithms.